For this purpose, we treated total PBMCs of COVID-19 patients with recombinant human Gal-9 (rhGal-9) (0.02 μg/ml), which mimics the mean detected Gal-9 level in the plasma, for 6 h. This evidence concerns the gene LGALS9 and COVID-19.